News archive
Showing 644 results
April 2012
-
Media ReleaseHigher dose of Novartis drug Exelon® Patch showed statistically significantly less decline in function in Alzheimer’s vs. lower dose• In the trial, patients on Exelon Patch 13.3 mg/24 h showed less functional decline vs. 9.5 mg/24 h patch in mild to moderate Alzheimer’s disease• Numerical trend toward cognitive efficacy was seen…
-
Media ReleaseHigher dose of Novartis drug Exelon® Patch showed statistically significantly less decline in function in Alzheimer’s vs. lower dose
-
Media ReleaseNew extension study data with Novartis drug Gilenya shows patients successfully treated for up to 7 years in relapsing MSResults from open label phase III extension and 7-year phase II extension studies show sustained low disease activity on clinical and MRI measures in patients continuing on Gilenya (fingolimod)…
-
Media ReleaseNew extension study data with Novartis drug Gilenya shows patients successfully treated for up to 7 years in relapsing MS
-
Media ReleaseNovartis announces update to United States prescribing information for MS therapy Gilenya following FDA reviewPrescribing information (PI) includes new patient selection parameters based on certain cardiovascular considerations to aid in identifying patients for GilenyaUpdated Gilenya prescribing information…
-
Media ReleaseNovartis announces update to United States prescribing information for MS therapy Gilenya following FDA review
-
Media ReleaseNovartis expands transplant portfolio with Hecoria®, the first generic tacrolimus that can be prescribed by brand nameNow available in US pharmacies, Hecoria (tacrolimus) capsules are approved for the prevention of organ rejection in certain kidney and liver transplant patientsHecoria, a branded generic, complements…
-
Media ReleaseNovartis expands transplant portfolio with Hecoria®, the first generic tacrolimus that can be prescribed by brand name
March 2012
-
Media ReleaseNovartis launches Arcapta™ Neohaler™, a novel once-daily bronchodilator for chronic obstructive pulmonary disease- Arcapta Neohaler is the only once-daily, 24-hour long-acting beta2-agonist approved for maintenance treatment of airflow obstruction in COPD patients- Arcapta Neohaler showed significant…
-
Media ReleaseNovartis launches Arcapta™ Neohaler™, a novel once-daily bronchodilator for chronic obstructive pulmonary disease